Part III: Guidelines for Selected Antimicrobial Use

3.7 Ceftaroline

Ceftaroline is an extended-spectrum cephalosporin with high affinity binding for penicillin-binding protein 2a (PBP2a) which accounts for its in vitro activity against MRSA. It is also active against Streptococcus pneumoniae. [240,241]
It is not active against ESBL-producing or AmpC-overexpressing Enterobacterales and has limited activity against non-fermenting Gram-negative bacilli such as Pseudomonas aeruginosa and Acinetobacter baumannii. [240]
Ceftaroline can be used to treat acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia. [242–245] Retrospective studies reported ceftaroline use in MRSA-related bacteraemia, endocarditis, or pneumonia. [246,247]
Dosing

Adults with normal renal function:

600 mg q12h or q8h, by intravenous infusion over 1 hour [135,248]

Dosage reduction is required in adult patients with creatinine clearance (CrCl) ≤50 mL/min and in end-stage renal disease including dialysis. [135]

Nausea, diarrhoea [249,250]

Rash, phlebitis [250]

Headache, insomnia, [249,250] encephalopathy [251]

Elevated liver enzymes [249]

Please consult a clinical microbiologist or infectious disease physician for the use of ceftaroline.